Aesica says its new high capacity manufacturing plant in the UK will ship diabetes treatment to markets worldwide.
The UK-based contract manufacturing organisation (CMO) opened the new £30m ($48m) facility in Queenborough, Kent earlier today, explaining that it will produce an unnamed solid dose treatment for adults with type 2 diabetes.
The 10,000 sq. m facility – which is due to start production in November – houses spray granulators, coaters, tablet presses, a delumper, blender and a sieve system and will employ a staff of 55 people.
Aesica told Outsourcing-pharma.com that products made at the plant will be distributed globally,
The firm declined to name the customer for which it will conduct manufacturing or confirm the duration of the manufacturing contract. The site already produces a range of other drugs.